HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters

Some studies do not list a clear city. Always confirm the location with the study team.

Some visits may still be in person. Participation depends on the study’s location and eligibility requirements.

290studies shown
Showing 193-204 of 290
Drug study icon
RecruitingNCT05980949

Long-term safety of KarXT for psychosis associated with Alzheimer’s disease

About this title

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Read the official source — NCT05980949
Official study title

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

In France
SchizophreniaMedication studyAges 55–90
Countries
France, United States, Canada, + 27 others
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Other study type icon
RecruitingNCT07129928

Staying active after depression rehabilitation

About this title

Organizational Strategies and Psychosocial Skills for Maintaining Physical Activity After a Depressive Episode: a 3-month Post-rehabilitation Study.

Read the official source — NCT07129928
Official study title

Organizational Strategies and Psychosocial Skills for Maintaining Physical Activity After a Depressive Episode: a 3-month Post-rehabilitation Study.

In France
DepressionObservational studyAges 18+
Countries
France
Sponsor
Hopital La Musse
Drug study icon
RecruitingNCT07029581

ACP-204 for psychosis in Lewy body dementia

About this title

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

Read the official source — NCT07029581
Official study title

A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

In France
SchizophreniaMedication studyAges 55–84
Countries
France, United States, Bulgaria, + 3 others
Sponsor
ACADIA Pharmaceuticals Inc.

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.